Category: nuclear imaging
RadioMedix $2.8 Million Grant from Texas Emerging Technology Fund to Result in New Products that Benefit Carcinoid and Neuroendocrine Cancer Patients
Two innovative products that will enable users to generate and label PET radiotracers on-site at a significantly reduced cost will be developed by RadioMedix, Inc. with a $2.8 million grant from the Texas Emerging Technology Fund. According to Ebrahim…
READ MORE
FDA Approves Novel Radio-peptide Targeted Therapy Clinical Trial for Neuroendocrine Cancer: PRRT (Peptide Receptor Radionuclide Therapy)
For the first time in North America, neuroendocrine cancer patients will have the opportunity to participate in a clinical trial of Lutetieum-177 (LU-177)with Octreotate. Ebrahim S. Delpassand, MD, chief executive officer and medical director of…
READ MOREImportant Octreoscan Update for U.S. & Canadian Carcinoid/NETs Patients
Octreoscans are again available in the United States and Canada! Production has resumed for Covidien’s Octreoscan Kit using Indium In-111 pentetreotide.…
READ MOREOctreoscan Test for Carcinoid & NET Patients Currently on Hold in U.S. and Canada
Due to a voluntary recall by the drug company Covidien, the Octreoscan Kit using Indium In-111 pentetreotide is not available at the present time in the United States or Canada. This means that carcinoid and neuroendocrine tumor patients cannot have…
READ MORE
